We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Angle Plc | AGL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.50 | 3.57% | 14.50 | 10:04:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 14.00 | 14.00 | 15.00 | 14.50 | 14.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 27/4/2024 13:42 by ohwhatfun HtFantasy highly unlikely, hence no comment. The whole company is loose change to them, why do the current deal, just acquire AGL. Random trashing is one thing, putting the pieces together is another. AGL have given their max timeline to cash running out based on all things going to plan. So the chat about funding needed isn’t fiction, it’s fact. You can’t leave it until late in the day. The share price just had a boost, if nothing else substantial is imminent then best crack on and get it done, results first though. |
Posted at 27/4/2024 09:33 by ohwhatfun HtThe market/city doesn’t care, max discount for max gains, what AGL do is not of interest to market makers. In other news Some are lurking investors not salivating shorters. AGL took its time but traction finally appearing, the historic cash burn does seem high though. It will be good to get the raise out of the way, bound to be some angry PIs if the market does to AGL (likely) what it has done to near all other small caps in recent times. |
Posted at 22/4/2024 09:44 by 5oletrader @gspanner gets it: In-house testing has shown that STANDARD laboratory TECHNIQUES, used WORLDWIDE, result in a high rate of CELL LOSS (>50%) and cause DAMAGE to CTCs. ?Cell Keep REDUCES COSTS by concentrating the CTCs into a smaller area on the slide, thereby LIMITING the quantity of HIGH COST antibodies and imaging TIME required to identify and analyse cells.- NO Contracts NO contracts NO contracts - is all I hear the negative nancy cry about - AGL maybe building out their services business (very professionally I might add) but you underestimate the PRODUCT side imo.- @gspanner was thinking the same as I - AGL have just unlocked a 'critical need' for the entire WORLDWIDE community who analyse CTCs including researchers, large pharma etc. ?As @gspanner eluded to - Sales of Cell Keep slides alone - what is that worth? I agree, certainly more than todays Market Cap. ?The fact AGL plan to sell it as part of kit - Portrait+ - says to me only one thing... Market Domination (Gold Standard). User buys a kit, has everything they need and instructions to follow - simplicity for the end user who now has a higher rate of CTCs than anyone else in the WORLD who opts to use an alternative product. |
Posted at 21/4/2024 16:24 by 5oletrader Something to keep an eye on?- ROCHE snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use ROCHE isn't content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations. With 1.5 BILLION Swiss francs ($1.65 BILLION) in 2023 sales, Alecensa is the top-selling med in the ALK inhibitor class, which also includes Takeda's Alunbrig and Pfizer's next-generation ALK/ROS1 inhibitor Lorbrena. ?Besides the adjuvant setting for resected tumors, ROCHE is also testing Alecensa in patients with locally advanced, unresectable, stage 3 NSCLC in the phase 3 HORIZON-01 trial.Https://www.fi |
Posted at 22/3/2024 09:30 by 5oletrader Re BBC article/grail/ctDNA. Some 'stuff' to ponder?-Is the Galleri test FDA approved? The Galleri test has NOT been cleared OR approved by the FDA.Https://assets.g |
Posted at 19/3/2024 23:27 by 5oletrader With just... One Business - AGL Lab ServicesWith just... One Customer - EISAIWith just... One FDA approval - BREASTEquates to just... One $451+M *OPPORTUNITY*-NOTE - Eisai has several ongoing trials with a number of investigational compounds and biological agents in various stages of development.-To AGL this equates to: 40,090 total patients $3,750 per blood sample 3 x time points (per patient)-40,090 x $3,750 = $150+MMultiply x 3 time points = $451+M-Opportunity (1) A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/?Metastati |
Posted at 11/3/2024 08:32 by radderssandy Hi Digger, I sent an email to IG (with help from another poster) towards the end of January. I also attended the Shares presentation in February and had a good chat with IG afterwards.As a LTH, I know AGL’s timelines can slip and it is frustrating. But I respect IG. He sent me a thorough & considered reply to my email (and it covered a number of topics) and I liked his lack of BS responses to my questions when I spoke to him. I asked him about the Solaris/prostate study. To summarise (Feb 2024) There is regular and ongoing dialogue between AGL & Solaris. Solaris understand the need for the work that is being undertaken and want the best results from the samples. The first part of the patient enrolment is done, which is the 100 samples (as per the Interim results). IG emphasised that these samples are “precious̶ They think prostate will get better results with RNA than DNA. IG said they anticipate the results coming out in H2. I said to IG that timelines have slipped and pushed it as far as I could do. It would appear that the company have “re-calibrated I think there is some ambiguity in the Interim’s presentation, I definitely understood it as being prostate & ovarian. But reading back the results RNS it is unspecific “Headline results from the Company's major clinical studies expected by the year end demonstrating key clinical applications of the Parsortix system for patient care”. The wording had changed in the November business update to “the first of which we expect to publish before the year end.” Which was the BiDetect. It will be interesting to see what the Prelim results say on the progress made. I don’t doubt that the results will be good, it’s just they prioritised BiDetect and most things with AGL, unfortunately, are slower than anticipated. |
Posted at 08/3/2024 10:39 by spa362 I agree. In fact AGL is no different from any other company at this stage of its cycle. The point here is that AGL has the advantage of a unique patented technology and FDA approval. ON that basis I am very happy to be a long term holder and am confident that commercial gains will follow - and that AGL will either grow considerably or (more likely) be bought out by a bigger fish at some point in the cycle. On the basis, the current valuation is far too low. Significant gains to come here for those that are prepared to be patient - far more likely than not...inevitably, there will be a price-moving RNS at some point |
Posted at 28/1/2024 09:10 by bones699 So let's talk about financial fundamentals here shall we rather than day dreaming chasing vanishing rainbows over the horizon. 🌈 🤔.Now Parsortix has been cleared for nearly two years and there is around 24 main cancer types of which only one has been approved by the FDA for testing breast cancer using the Parsortix machine. So here is the conundrum not only has AGL generated virtually no sales revenues in two years despite having approval for breast cancer treatment but to generate sales it is unwilling to complete the testing required for the remaining 23 cancer types expecting the third party labs to do this themselves. Well it doesn't take a rocket scientist to figure out that to date LabCorp and Quest Diagnostics the two USA leading lab company's has shown next to no interest in buying Parsortix machines due no doubt to the severe limitation in cancer testing. Hence Newlands claim at the recent Investor Meet that third party labs are likely to take on Parsortix and seek their own accreditation because that is exactly what he was alluding too appear unfounded! As to date non of the big USA lab chains have done what Newland claimed they would do in nearly two years since FDA clearance!... We can now see that the financial fundamentals are beginning to fall apart, low cash balances c.£12m at best, a high monthly cash burn rate over £1.4m and Newland claiming that an additional £6m revenues will occur out of apparently thin air only reference at the Investor Meet by their CFO looking quite twitcher I might add when asked about the cash runway was funding would be from 'strategic opportunities' and 'project milestones' whatever that was meant to mean before alluding to tapping the market as in the past, just gave the game away don't you think! So there we have the crux of the matter a business running out of both time and money before the next eventual cash raise. Meanwhile the market has now cottoned on to Newlands tricks ramping RNS releases all of which lack financials and timelines with the seeming sole objective to keep the share price up ahead of a potential cash raise to mitigate the size and scale of yet another damaging £20m share issuance, to chuck onto the pile of burnt investor cash over £130m to date, and at what share price 12p or much less by the look of things.. Meanwhile other competitors are entering the market space and closer to full FDA approval than AGL while 'BIG PHARMA' could have picked AGL up for under 10p and show no interest, no surprises there then! AGL should carry a government health warning that these 🌈's are never free and can and do fade over time! |
Posted at 17/1/2024 20:22 by 5oletrader Anyone else find the ref to EISAI interesting? 80 ACTIVE oncology trials 60,000 Participants 3 potential Timelines for SAMPLING patient blood (before, during, after) AGL state sliding scale charge for processing blood samples - range from £1k to £5k (say average at £3k ?)AM I RIGHT WITH THIS??? 180,000 samples x £3k sample charge = £540M of potential opportunity for AGL with just ONE large Pharma customer? -Re Distributors: Good to see 100+ boots on the ground - fully trained staff (establishing global presence) Nicely Incentivised at 30% commission re sales-HOCKEY STICK revenue referenced once again with: 2024 revenues expected to AT LEAST treble.-Re the Parsortix Machine itself: Easy to Use One (1) of AGLs technicians is capable of running twenty (20) machines simultaneously - impressive?-Re ILLUMINA: generating $4B in sequencing revenues approx 3000 illumina systems in current use Financially - Plugin the 'Parsortix Inside' technology with above - fruitful partnership?-Re Ovarian: AGL currently using in house molecular platform Want to MOVE it across to Illumina and ThermoFisher systems. WHY?-Re DDR Inhibitors Summit: AGL attending DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. ASTRAZENECA and MERCK reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like ROCHE and GILEAD are diving into this therapeutic strategy; biotech companies like ARTIOS and IDEAYA remain dedicated todelivering safe and effective treatments to patients. https://ddr-inhibito |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
